Exploring the heterogeneity of hepatic and pancreatic fat deposition in obesity: implications for metabolic health.


Journal

Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782

Informations de publication

Date de publication:
2024
Historique:
received: 12 06 2024
accepted: 19 09 2024
medline: 23 10 2024
pubmed: 23 10 2024
entrez: 23 10 2024
Statut: epublish

Résumé

This retrospective observational study investigates the heterogeneity of hepatic and pancreatic fat deposition and its implications for metabolic health in individuals with obesity. A total of 706 patients with obesity underwent an MRI to quantify liver and pancreatic fat. Patients were classified into four groups based on fat deposition: no fat (None), fatty pancreas only (NAFPD), fatty liver only (NAFLD), and both conditions (NAFLD+NAFPD). Biochemical profiles, insulin resistance (Homeostatic Model Assessment for Insulin Resistance, HOMA-IR), and β-cell function were analyzed. A series of multiple linear regressions were used to investigate the independent effects of characteristics on glucose, insulin, and C-peptide at 0h. Another multiple linear regression was performed to evaluate the effects of basic characteristics on average liver fat, mean pancreatic fat, and visceral fat. The majority (76.63%) exhibited both NAFLD and NAFPD, highlighting the heterogeneity of fat deposition among individuals with obesity. Groups with fatty liver displayed significantly higher fasting glucose, insulin, C-peptide, and HOMA-IR levels than those without fatty liver (P < 0.01). Fatty pancreas alone did not significantly influence these metabolic parameters (P > 0.05). This underscores the greater metabolic impact of hepatic fat compared to pancreatic fat. The study confirms the complex heterogeneity of fat deposition in obesity, with the fatty liver being a more influential factor in metabolic disturbances than the fatty pancreas. The prevalent co-occurrence of NAFLD and NAFPD in this population underscores the need for targeted management strategies focusing on hepatic fat reduction to mitigate metabolic risk.

Identifiants

pubmed: 39439559
doi: 10.3389/fendo.2024.1447750
pmc: PMC11493592
doi:

Substances chimiques

Blood Glucose 0

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

1447750

Informations de copyright

Copyright © 2024 Deng, Li, Chen, Wang, Sun, Tang, Luo, Zhang, Xu and Dai.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Auteurs

Ming Deng (M)

Department of Radiology, Zhongnan Hospital of Wuhan University, Wuhan University, Wuhan, China.
Hubei Provincial Engineering Research Center of Multimodal Medical Imaging Technology and Clinical Application, Wuhan, China.
Wuhan Clinical Research and Development Center of Brain Resuscitation and Functional Imaging, Wuhan, China.

Zhen Li (Z)

Department of Hepatobiliary and Pancreatic Surgery, Zhongnan Hospital of Wuhan University, Wuhan University, Wuhan, China.

Shangyu Chen (S)

Department of Endocrinology, Zhongnan Hospital of Wuhan University, Wuhan University, Wuhan, China.
Department of Endocrinology and Metabolism, Guangxi Academy of Medical Sciences and the People's Hospital of Guangxi Zhuang Autonomous Region, Guangxi, Nanning, China.

Huawei Wang (H)

Department of Endocrinology, Zhongnan Hospital of Wuhan University, Wuhan University, Wuhan, China.

Li Sun (L)

Department of Endocrinology, Zhongnan Hospital of Wuhan University, Wuhan University, Wuhan, China.

Jun Tang (J)

Department of Endocrinology, Zhongnan Hospital of Wuhan University, Wuhan University, Wuhan, China.

Liman Luo (L)

Department of Endocrinology, Zhongnan Hospital of Wuhan University, Wuhan University, Wuhan, China.

Xiaoxiao Zhang (X)

Department of MSC Clinical & Technical Solutions, Philips Healthcare, Beijing, China.

Haibo Xu (H)

Department of Radiology, Zhongnan Hospital of Wuhan University, Wuhan University, Wuhan, China.
Hubei Provincial Engineering Research Center of Multimodal Medical Imaging Technology and Clinical Application, Wuhan, China.
Wuhan Clinical Research and Development Center of Brain Resuscitation and Functional Imaging, Wuhan, China.

Zhe Dai (Z)

Department of Endocrinology, Zhongnan Hospital of Wuhan University, Wuhan University, Wuhan, China.
Department of Clinical Nutrition, Zhongnan Hospital of Wuhan University, Wuhan University, Wuhan, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH